HIGHFDA DRUG

Omnipaque Injection Recalled by GE Healthcare for Particulate Matter in 866,570 vials (2026)

GE Healthcare recalled Omnipaque iohexol injection, 300 mg/mL, distributed nationwide in the United States. The Class II recall covers 866,570 vials due to particulate matter. Healthcare providers should stop use and contact GE Healthcare Ireland Limited for guidance.

Official notice
OMNIPAQUEGE Healthcare Inc.Health & Personal CareDrugs & MedicationsLot# 17225029Exp. September 32028 Lot# 17265376

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 24, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
March 24, 2026
Hazard Level
HIGH
Brands
OMNIPAQUE, GE Healthcare Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, ELDERLY

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
OMNIPAQUE, GE Healthcare Inc.
Product type
Injection
Model numbers
Lot# 17225029, Exp. September 3, 2028 Lot# 17265376, Exp. October 3, 2028 Lot# 17270885, Exp. September 10, 2028 Lot# 17292246, Exp. October 4 +12 more
UPC codes
0407-1401, 0407-1411, 0407-1412, 0407-1413, 0407-1414, 0407-1415, 0407-1416, 0407-1401-52 +9 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 24, 2026

  2. Reported by FDA DRUG

    April 15, 2026

  3. RecallRadar source check

    April 22, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Presence of particulate matter

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact GE Healthcare Ireland Limited or your healthcare provider for guidance

About This Product

Omnipaque iohexol injection is a contrast agent used in radiologic imaging. It helps visualize blood vessels and tissues during CT or fluoroscopy.

Why This Is Dangerous

The product contains particulate matter which can cause injection-related complications depending on the material and sterility.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Hospitals and clinics must identify affected lots, quarantine them, and follow disposal protocols. No user-level consumer data provided.

Practical Guidance

How to identify if yours is affected

  1. Review lot numbers and expiry dates against the recall list
  2. Check NDC 0407-1413-63 on packaging
  3. Inspect vials for particulates during handling
  4. Quarantine affected inventory immediately

Where to find product info

FDA enforcement report D-0447-2026 and GE Healthcare recall communications

What timeline to expect

Facilities may take 4-6 weeks for disposition or replacement of affected lots

If the manufacturer is unresponsive

  • Escalate to institutional recall coordinator
  • Contact GE Healthcare regional office for escalation
  • Consult FDA for further guidance

How to prevent similar issues

  • Establish strict inbound inspection for sterile injectables
  • Verify NDC and lot/date codes before use
  • Maintain separation of affected inventory from stock for quick quarantine

Documentation advice

Maintain lot lists, disposal records, and correspondence with GE Healthcare

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Brand: OMNIPAQUE (iohexol). Distributor: GE Healthcare Inc., Marlborough, MA. NDC: 0407-1413-63. Quantity: 866,570 vials. Formulation: 300 mg/mL (64.7%). Route: Injectable Rx only. Sold nationwide in the U.S. via healthcare supply channels. Expiry dates mentioned in lot details (e.g., Exp. Sept 3 2028, Exp. Oct 3 2028, etc.). Lot numbers listed in safety notice.

Reported Incidents

No specific consumer injury or adverse event data provided in the recall notice.

Key Facts

  • Particulate matter detected
  • Distributed nationwide in the U.S.
  • Lots with expiry in 2028 (Sept 3, Oct 3, Oct 18, Oct 20, Oct 4, Oct 5, Oct 19, Nov 25)

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTELDERLYPREGNANT
Injury Types
POISONINGLACERATIONELECTRICALOTHER

Product Details

Model Numbers
Lot# 17225029
Exp. September 3
2028 Lot# 17265376
Exp. October 3
2028 Lot# 17270885
+15 more
UPC Codes
0407-1401
0407-1411
0407-1412
+14 more
Affected States
ALL
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more